Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12109230

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12110491

    Selective reduction of allelic variants

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12109296

    Peptide exhibiting wrinkle-improving activity and uses thereof

    CAREGEN CO., LTD. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12109231

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12109236

    Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function

    Regents of the University of Minnesota · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12109239

    Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof

    Astellas Institute for Regenerative Medicine · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12109228

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12110504

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12109260

    Zika vaccines and immunogenic compositions, and methods of using the same

    Takeda Vaccines, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12109201

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12110344

    Antibodies that bind to cis and uses thereof

    DIANTHUS THERAPEUTICS OPCO, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12108745

    Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment

    Northwestern University · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12110315

    Fish-derived peptidoglycan recognition protein mutant and application thereof

    OCEAN UNIVERSITY OF CHINA · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12110334

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12110343

    Anti-plasma kallikrein antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12109229

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12110502

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12109225

    Methods for potentiating cancer treatment using ionizing radiation

    GLYCOMIRA THERAPEUTICS, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12109190

    Urolithins as immune response enhancers

    Amazentis SA · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12109185

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12109197

    Combinations of β-lactam compounds and probenecid and uses thereof

    Iterum Therapeutics International Limited · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 2024335360

    PRESSURIZED NANOEMULSION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 2024335380

    NANOEMULSION WITHOUT PROPYLENE GLYCOL

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    ALFASIGMA S P A [IT] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2024211523

    SCHÉMAS POSOLOGIQUES DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION DE LA RECHUTE DE LA LEUCÉMIE MYÉLOÏDE AIGUË APRÈS UNE TRANSPLANTATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ALLOGÉNIQUES AVEC DU VÉNÉTOCLAX EN COMBINAISON AVEC DE L'AZACITIDINE

    ABBVIE INC [US] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. WO 2024209064

    NANOÉMULSION SANS PROPYLÈNE GLYCOL

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. WO 2024209065

    NANOÉMULSION SOUS PRESSION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12116423

    Ang (1-7) derivative oligopeptides and methods for using and producing the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12116416

    Targeting intracellular target-binding determinants with intracellular antibodies

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12116343

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12115166

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12116574

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12116589

    Treatment of amyotrophic lateral sclerosis (ALS)

    VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12116596

    Method and apparatus for improved mesenchymal stem cell harvesting

    Elite IP, LLC · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12116606

    Complement factor I-related compositions and methods

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12115216

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12116405

    Arthritis treatment

    XBIOTECH INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12115198

    Microbials for animals

    MICROBIAL DISCOVERY GROUP, LLC · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12115183

    Synthetic melanin nanoparticles and uses thereof

    The Regents of the University of California · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12115165

    Use of reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.